I’ve just read this announcement & how fantastic for us to have Prof Packham on board as CMO & also heading our medical advisory board.
His credentials are exceptional as a nephrologist, both as a physician and his 30+ years of experience in clinical trials. Welcome David if you are reading this. Sure you wouldn’t have much time lately.
Clearly Team DXB have been so busy crossing every t & dotting every i in reviewing 2a, planning & implementing trial designs & carefully choosing sites for trials & participants for 2b trials. That sounds so simple...I can just imagine the complexities, particularly the synergies between both FSGS & diabetic nephropathy trials, that was mentioned more than once in the announcement.
Really looking forward to seeing this all unfold & come to fruition in the coming months. Particularly that FSGS mostly affects kids & adolescents. They still have their whole life ahead of them, and if this can make a massive difference, all the better.
Ps we had a great time at the Sydney Royal Easter Show today.
I’ve just read this announcement & how fantastic for us to have...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.0¢ | 36.0¢ | $870.7K | 2.355M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 107188 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 4504 | 1 |
View Market Depth
| Last trade - 16.10pm 04/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |